Showing 3821-3830 of 6950 results for "".
- Registration Open for ISHRS Hybrid World Congresshttps://practicaldermatology.com/news/registration-open-for-ishrs-hybrid-world-congress/2460902/The 29th Meeting of the International Society of Hair Restoration Surgery (ISHRS) is coming October 21-23. Registration is now open for the Hybrid World Congress 2021, with the i
- UV Index Today is Helping to Reduce Skin Cancer Rates with Web Technologyhttps://practicaldermatology.com/news/uv-index-today-is-helping-to-reduce-skin-cancer-rates-with-web-technology/2460891/UV Index Today launched their free UV forecasting service to help people track the sun’s ultraviolet radiation
- New Survey: Americans Have Missed Out on Dating, Parties, School And Work Because of Acnehttps://practicaldermatology.com/news/new-survey-americans-have-missed-out-on-dating-parties-school-and-work-because-of-acne/2460889/Americans missed out on dating, school and hanging out with friends because of acne during the past year, according to a new survey by University Medical, the manufacturer of the Acne Wipeout skincare system. After more than a year of looking at themselves on screens and hiding behind s
- Rinvoq Has Quicker Onset, Higher EASI Scores than Dupixent in Phase 3b Study of Adults with Atopic Dermatitishttps://practicaldermatology.com/news/rinvoq-bests-dupixent-in-phase-3b-study-of-adults-with-atopic-dermatitis/2460882/AbbVie’s JAK Inhibitor Rinvoq (upadacitinib) performed better than Dupixent (dupilumab) for primary and all ranked secondary endpoints in a phase 3b head-to-head study in adults with atopic dermatitis (AD), according to a
- Bausch Health Plans IPO of Solta Medical Aesthetics Unithttps://practicaldermatology.com/news/bausch-health-plans-ipo-of-solta-medical-aesthetics-unit/2460880/Bausch Health Companies Inc. is planning to pursue an initial public offering (IPO) of its Solta Medical business. Solta’s portfolio includes the Thermage RF systems, Fraxel laser, Clear + Brilliant laser and VASER ultrasonic systems. The timing of the anticipated IPO, w
- Hot Off the Press: Dr. Brooke Jackson’s New Book “Skin Care for Runners” Now Availablehttps://practicaldermatology.com/news/hot-off-the-press-dr-brooke-jacksons-new-book-skin-care-for-runners-now-available/2460875/Durham, NC-based dermatologist Dr. Brooke Jackson’s new book, “Skin Care for Runners”, is now available. The book is the definitive guide to healthy skin and nails for runners—and all athletes. In it, Dr. Jackson, also marathoner, offers tips and
- Sasakawa Leprosy (Hansen's Disease) Launches New "Don't Forget Leprosy" Initiativehttps://practicaldermatology.com/news/sasakawa-leprosy-hansens-disease-new-initiative-dont-forget-leprosy/2460872/Sasakawa Leprosy (Hansen's Disease) Initiative is launching a campaign called "Don't Forget Leprosy" urging that activities against the disease are not sidelined amid the ongoing coronavirus pandemic. Beginning with a webinar on Aug. 4, 2021, the approximately 10-
- Survey: Cleansing Habits of Americans Are Not Up to Dermatologist Standardshttps://practicaldermatology.com/news/survey-cleansing-habits-of-americans-are-not-up-to-dermatologist-standards/2460871/Fully 91 percent of consumers agree that cleansing is important, only 23 percent say that a dermatologist would be pleased with their facial cleansing habits, according to a new survey conducted by CeraVe of 2,000 U.S. adults aged 18-40. This is why this CeraVe is helping
- LiVDerm Brings SBS Part II to Hollywood, FL this Fallhttps://practicaldermatology.com/news/livderm-brings-sbs-part-ii-to-hollywood-fl-this-fall/2460868/SBS Part II: The Aesthetic Dermatology Summit comes to Hollywood, FL, September 23-25, closing out the two-part 19th Annual South Beach Symposium. Produced by LiVDerm, the event is centered on the latest and most re
- PASI-HD: Modification to PsO Severity Scale Aims at Mild-to-Moderate Diseasehttps://practicaldermatology.com/news/pasi-hd-modification-to-pso-severity-scale-aims-at-mild-to-moderate-disease/2460867/A new modification to the Psoriasis Area and Severity Index (PASI) aims to address limitations of the scale when used to assess mild-to-moderate disease. PASI-high discrimination (PASI-HD), designed to be used in clinical trials among patients for whom the areas of affected body surface are less